Continuous subcutaneous infusion of apomorphine, a dopamine agonist, is an effective treatment option for motor fluctuations in Parkinson disease (PD). In a trial of 106 patients with PD and refractory motor fluctuations, apomorphine infusion both reduced “off” time and improved “on” time without dyskinesias by approximately two hours compared with placebo (saline) infusion . The most common side effects were skin site reactions and nausea. Continuous subcutaneous apomorphine infusion is under review by the US Food and Drug Administration and is already available in Europe. (See “Device-assisted and surgical treatments for Parkinson disease”, section on ‘Efficacy of CSAI’.